On February 5, 2025, BGI Genomics’ Indonesian joint venture, PT Naleya Genomik Indonesia (NGI), officially signed a partnership agreement for research collaboration with Rumah Sakit Anak dan Bunda - National Women and Children Health Center (RSAB) Harapan Kita. The collaboration focuses on the extended Non-Invasive Prenatal Test (NIPT-Pro) and Copy Number Variation Sequencing (CNVseq) to advance prenatal genetic screening technology in Indonesia. <img src="https://cdn.it.bgi.com/source/BGI+Genomics+JV+NGI+signed+research+collaboration+with+RSAB+Harapan+Kita.jpg" alt="BGI+Genomics+JV+NGI+signed+research+collaboration+with+RSAB+Harapan+Kita.jpg" data-href="" style="width: 100%;">Wang Jian, Heru Dharmadi Wijaya, Ockti Palupi Rahayuningtyas, Azhar Jaya, and Dra. Lucia Rizka Andalucia.The agreement was signed by Dr. Ockti Palupi Rahayuningtyas, MPH, MH.Kes, President Director of RSAB Harapan Kita, and Heru Dharmadi Wijaya, President Director of NGI. The signing was also witnessed by Dr. Dra. Lucia Rizka Andalucia, Apt, M. Pharm, MARS, Director General of Pharmaceuticals and Medical Devices, Dr. Azhar Jaya, S.H., SKM, MARS, Director General of Advanced Health Services, and Wang Jian, Co-Founder and Chairman of BGI Group. “This research is designed to apply NIPT-Pro, a genetic test based on massively parallel sequencing technology, for detecting chromosomal aneuploidy and Copy Number Variations (CNV) among pregnant women in Indonesia. In its implementation, high-risk NIPT-Pro results, along with ultrasound findings indicating potential risks, will be further confirmed using CNV sequencing (CNVseq) technology on the amniotic fluid of the respective pregnant women,” said Heru Dharmadi.The CNVseq technology is Indonesia’s first prenatal diagnostic innovation, designed to provide comprehensive detection of chromosomal abnormalities, including aneuploidy, triploidy, and various types of CNV disorders. With a high level of accuracy, this technology plays a crucial role in supporting precise clinical decision-making to safeguard maternal and fetal health.Dr. Ockti stated, “We welcome this collaboration as it brings significant benefits to pregnant women in Indonesia by enabling early detection of fetal genetic disorders. We hope this research serves as the first step toward developing more advanced, accurate, and rapid prenatal screening and diagnostics, positioning NIPT as an alternative modality for first-tier genomic screening for all pregnant women.”This initiative aligns with the healthcare transformation pillars promoted by the Ministry of Health of the Republic of Indonesia, particularly the advancement of healthcare technology. Through this innovation, pregnant women in Indonesia are expected to gain access to safer, more accurate, comprehensive, and affordable prenatal screening methods, enabling better anticipation and management of genetic disorders during and after pregnancy.Non-Invasive Prenatal Testing (NIPT) is a genetic screening method that detects chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome as early as the 10th week of pregnancy. It analyzes fetal DNA in the mother’s blood using high-throughput sequencing technology. NIPT-Pro, as an extended version, allows for the detection of additional chromosomal abnormalities, including microdeletion and microduplication syndromes. Through this research, BGI Genomics and RSAB Harapan Kita are committed to delivering more accurate and accessible prenatal diagnostic innovations for a broader population of pregnant women across Indonesia. About BGI Genomics<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.Read：<a href="https://www.bgi.com/global/news/bgi-genomics-brunei-cervical-cancer-prevention" target="_blank">BGI Genomics Empowers Brunei’s National Cervical Cancer Prevention Program</a><a href="https://www.bgi.com/global/news/pakistani-delegation-strengthens-partnership-with-bgi-genomics" target="_blank">Pakistani Delegation Strengthens Partnership with BGI Genomics in Precision Medicine</a><a href="https://www.bgi.com/global/news/bgi-genomics-welcomes-saudi-health-minister-to-witness-partnership-signing" target="_blank">BGI Genomics Welcomes Saudi Health Minister to Witness Partnership Signing</a>

BGI Genomics' Joint Venture NGI Signed Research Agreement for Prenatal Genetic Screening in Indonesia

<img src="https://cdn.it.bgi.com/source/science+times.png" alt="science+times.png" data-href="" style="width: 100%;">In a recent feature by <a href="https://www.sciencetimes.com/articles/60284/20250207/bgi-genomics-tif-supports-high-throughput-sequencing-key-advancing-thalassemia-prevention.htm" target="_blank">The Science Times</a>, BGI Genomics and the Thalassemia International Federation (TIF) were highlighted for their joint webinar on thalassemia prevention. The discussion focused on the role of high-throughput sequencing (HTS) in improving early diagnosis, reducing misdiagnosis, and enhancing screening efficiency worldwide. Experts from multiple countries shared insights on the latest advancements in genetic testing and its impact on thalassemia management. Read the full coverage below. The Thalassemia International Federation (TIF) and BGI Genomics gathered at a webinar on thalassemia prevention to discuss advances in the condition's diagnosis using high-throughput sequencing (HTS) genetic testing.Thalassemia is a blood disorder that reduces the body's ability to produce hemoglobin, which is used by red blood cells to carry oxygen throughout the body. This condition causes a significant health burden across the world, particularly in Southeast Asia, the Mediterranean, and parts of Africa. As Professor Sakorn Pornprasert of Chiang Mai University described, with 800,000 annual births, over 4,200 babies could be born with severe conditions, resulting in an estimated societal cost of $612 million USD over their lifetimes.When treating thalassemia, many countries struggle with low screening rates and high misdiagnosis risks, leading to increased healthcare costs and delayed treatment. In recent years, HTS genetic testing has become an emerging diagnostic method for the condition due to its high accuracy, speed, and cost-effectiveness.Speaking about this issue, Dr. Peng Zhiyu, vice president of BGI Genomics, explained that HTS-based genetic testing offers a significant improvement over conventional hematological analysis, which often requires multiple blood tests and clinic visits and may still fail to detect uncommon gene mutations. HTS provides more accurate screening results, reducing false negatives and improving prenatal diagnosis. Furthermore, Dr. Peng stated that HTS improves carrier and at-risk couple identification without added costs compared to traditional methods.Other experts on the panel also supported HTS's effectiveness. Dr. Dina Garniasih from Indonesia's Harapan Kita Hospital reported improved outcomes after integrating HTS into their testing protocol, while Professor Zhu Baosheng from China's Yunnan Province emphasized HTS's superior accuracy over traditional methods.Given the high interest within the medical community, BGI formed an international academic consortium for thalassemia prevention, currently spanning China, Thailand, Malaysia, Indonesia, and Vienna. The consortium offers free pilot project implementation, training programs, and HLA typing services, having completed 20,000 tests across 7,000 families.Finally, Dr. Michael Angastiniotis, Medical Advisor at TIF, underscored the importance of public education in thalassemia prevention. He also noted that many thalassemia-prevalent countries face blood donation shortages, creating additional challenges for transfusion-dependent patients.<h4> &nbsp;</h4><h4>Read more: </h4><a href="https://www.bgi.com/global/news/hts-technology-accelerates-global-thalassemia-prevention" target="_blank">High-throughput Sequencing Technology Accelerates Global Thalassemia Prevention | TIF Webinar Recap</a>

BGI Genomics and TIF Supports High-Throughput Sequencing as Key to Advancing Thalassemia Prevention | The Science Times

Every minute, 38 people are diagnosed with cancer, and 18 people die from it globally, according to the World Health Organisation, and it's estimated to increase by 77% to 35 million in 2050. But what if we could predict cancer risks before they even develop? Genetic testing helps detect cancer risks early, making it essential for cancer prevention and control.<img src="https://cdn.it.bgi.com/source/WCD_First+photo+Edited.png" alt="WCD_First+photo+Edited.png" data-href="" style="width: 100%;"/>As the world marks World Cancer Day on February 4, under the theme “United by Unique” of &nbsp;2025-2027, the conversation around personalized medicine and accessible screening options has never been more relevant. Advanced DNA-based new innovations are ensuring that cancer care is more effective and accessible.Early Screening Improve Survival RateCancers, like colorectal, breast, and cervical cancer, are highly treatable if caught early. Yet millions of people avoid screening altogether, often because traditional tests are invasive, expensive, inconvenient, or intimidating. For colorectal cancer (CRC), one of the most preventable yet deadliest cancers, the numbers are clear: if caught in its earliest stage, the five-year survival rate is over 90%. But when diagnosed late, survival drops to just 14%.Colonoscopies, the gold standard for CRC screening, require fasting, laxative preparation, and a hospital visit, which can be enough to make someone put it off indefinitely. The complicated preparation makes it easy for people to put it off indefinitely. In many cases, people simply don’t realize they’re at risk until symptoms appear—by which time, treatment is far more difficult. &nbsp;Screening Needs to be AccessibleTraditional cancer screening methods aren’t just uncomfortable—they’re also a major reason why screening rates remain low worldwide. To tackle these barriers to early screening, DNA-based stool testing as an innovative approach, is offering an easier, non-invasive and promising alternative that can catch cancer early.Last year, we covered Uncle Ren’s colorectal cancer screening story in Hangzhou, China. Another participant in the same public health program, Uncle Jiang, had never been screened for CRC before. When his test results came back positive for abnormal biomarkers, he immediately feared the worst. <img src="https://cdn.it.bgi.com/source/WCD_Uncle+Jiang+story+Edited.png" alt="WCD_Uncle+Jiang+story+Edited.png" data-href="" style="width: 100%;"/>"I thought it was over. Maybe it was already late-stage cancer," he recalled.With the help of his family doctor, he went to a specialized hospital for a colonoscopy. The night before the procedure, however, turned out to be almost as stressful as waiting for the results.He recalled going to the toilet every fifteen minutes. "If you ask for a colonoscopy at the beginning, even if it is a free test, I probably won't choose it. It won't stop all night." He said reluctantly. Fortunately, the colonoscopy revealed that he had a tubular adenoma, a precancerous condition, and six polyps were removed, eliminating his health risks. Uncle Jiang’s story isn’t unique. Millions avoid screening due to inconvenience or fear—but when non-invasive options like stool DNA tests become available, more people get tested, more cases are caught early, and more lives are saved. Non-invasive Method Improves Screening RateTo address low screening rates, researchers and healthcare providers are turning to DNA-based stool testing, a game-changing alternative to traditional colonoscopy. "The best screening method is the one that the patient accepts and adheres to because that’s the method that will actually benefit them," Prof. Varut Lohsiriwat, professor of surgery in the Division of General Surgery (Section of Colorectal Surgery) from Siriraj Hospital, Mahidol University highlighted in an interview. <img src="https://cdn.it.bgi.com/source/WCD_COLOTECT_Edited.png" alt="WCD_COLOTECT_Edited.png" data-href="" style="width: 100%;"/>Tests like BGI Genomics’ COLOTECT&reg; multi-target stool DNA test provide a painless, at-home alternative to colonoscopy for early CRC detection. The <a href="https://www.bgi.com/global/news/stool-dna-testing-for-crc-detection-thailand" target="_blank">recent study</a> lead by Prof. Varut Lohsiriwat’s team in Thailand found that stool DNA testing is highly effective, offering an accurate and accessible alternative to invasive screening among the Thai population. As a reliable alternative to colonoscopy, multitarget DNA testing can highly improve the accessibility and compliance rate for the general public in the recommended screening target age group. A study found that the availability of multitarget stool DNA (mt-sDNA) colorectal cancer screening led to high screening compliance of 88% and diagnostic colonoscopy compliance on mt-sDNA positive cases of 96%, published in <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5291851/#:~:text=Core%20tip%3A%20The%20availability%20of,a%20multi%2Dspecialty%20group%20practice" target="_blank">World Journal of Gastroenterol</a> in 2017. By making early detection simple and accessible, more people will get screened—and fewer cases will advance to life-threatening stages.Prevention Starts SmallWhile genetic screening helps detect cancer early, healthy lifestyle choices remain a crucial defense against developing cancer in the first place. Up to 40% of cancers diagnosed and nearly half of cancer deaths could be prevented through lifestyle changes, according to a study published in <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21858" target="_blank">CA: A Cancer Journal for Clinicians</a>. <img src="https://cdn.it.bgi.com/source/WCD_exercise+Edited.png" alt="WCD_exercise+Edited.png" data-href="" style="width: 100%;"/>Another study, published in <a href="https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.818470/full" target="_blank">Frontiers in Molecular Biosciences</a> in 2022, shows that high-intensity exercise can suppress tumor growth by influencing key cancer-related genes. The researcher used High-throughput sequencing to identify differentially expressed genes (e.g., Trim63, Fos, Col1a1, Six2) regulated by this exercise, which negatively impacted colorectal cancer development. These effects were confirmed in vitro.Exercise's tumor-suppressive effects depend on type, intensity, frequency, and cancer type, necessitating personalized exercise interventions. This study used mice subjected to high-intensity aerobic exercise (90% of maximal heart rate) to highlight the importance of preventive exercise and an exercise-centered lifestyle.<img src="https://cdn.it.bgi.com/source/WCD_Balanced+Diet.png" alt="WCD_Balanced+Diet.png" data-href="" style="width: 100%;"/>The <a href="https://www.wcrf.org/preventing-cancer/topics/fibre-wholegrains-and-cancer/#:~:text=Our%20research%20shows%20that%20eating,the%20risk%20of%20bowel%20cancer.&text=Our%20research%20also%20shows%20that,least%2013%20types%20of%20cancer." target="_blank">World Cancer Research Fund (WCRF)</a> has also reported that diets rich in vegetables, whole grains, and lean proteins significantly reduce cancer risk, while smoking alone is responsible for one in five cancer deaths worldwide.Prevention doesn’t have to mean drastic lifestyle overhauls. Small, consistent changes—more movement, healthier eating, and cutting back on harmful habits—can make a big difference in reducing cancer risk over time.As World Cancer Day 2025 approaches, it’s a reminder that while each cancer journey is different, we all share the same goal: reducing cancer’s impact. Cancer doesn’t play fair—but with better screening, smarter prevention, and early action, we can change the future. About COLOTECT&reg;<a href="https://cdn.it.bgi.com/source/%E3%80%90flyer%E3%80%91colotect-v1-2409.pdf" target="_blank">COLOTECT</a>&reg; is a non-invasive fecal DNA test developed by BGI Genomics for detecting CRC and precancerous lesions. It uses multiplex methylation-specific PCR (MSP) technology to trace abnormal DNA-methylation biomarkers in CRC from stool samples. COLOTECT&reg;&reg; has a sensitivity of 88% for detecting CRC, and a sensitivity of 46% for the early detection of advanced adenomas—both of which outperform conventional fecal tests. &nbsp;About BGI Genomics<a href="bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.Read:<a href="https://www.bgi.com/global/news/stool-dna-testing-for-crc-detection-thailand" target="_blank">Research Proves Stool DNA as Non-Invasive Alternative for Colorectal Cancer Screening | BGI Insight</a><a href="https://www.bgi.com/global/news/colorectal-cancer-survivor-uncle-rens-story" target="_blank">"I was saved from the silent killer – colorectal cancer" | Uncle Ren’s Story</a><a href="https://www.bgi.com/global/news/will-colorectal-cancer-become-a-chronic-disease-bgi-insight" target="_blank">Will Colorectal Cancer Become a Chronic Disease? | BGI Insight</a>

Early Screening and Lifestyle Changes Prevent Nearly Half Cancer Cases | World Cancer Day

Exciting news! As spring approaches, we're overjoyed to present these incredible promotions, allowing you to explore your groundbreaking discoveries with ease and without the stress of budget concerns. <img src="https://cdn.it.bgi.com/source/600x1200banner.jpg" alt="600x1200banner.jpg" data-href="" style="width: 50%;"> Whole-genome Sequencing from 25HKD/Gb Clean Data• This promotion is applicable to human, plant&amp;animal, and microbial samples.• The type of library is PCR-based library.• Sequencing is performed on DNBSEQTM, PE150. DNBelab C Series Single Cell RNA Sequencing from 18,000HKD/2 Samples• Please send cell suspension in pairs.• Including cell QC, library construction, sequencing and standard analysis.• The sequencing is performed on DNBSEQTM, PE100, with an output data volume of approximately 600M raw reads per sample. 30% Off All Mass Spectrometry-Based Services• This promotion is applicable to proteomics and metabolomics.• Including sample extraction, LC-MS/MS detection and standard analysis.• The detection is performed on Orbitrap Astral, Orbitrap Exploris 480, Orbitrap Fusion Lumos, or Q-Exactive HF-X, etc. Time is limited for the promotional pricing. <a href="https://cdn.it.bgi.com/source/limited-time-promotion-202501.pdf" target="_blank">Open the Flyer</a> to learn more, or contact us at info@bgi.com for a free consultation! Promotion Terms and Conditions:• This promotion cannot be accumulated with any other offers.• Services are for research use only.• If more data is required, the customer will need to pay for the additional data fees.• The promotion terms are only eligible for contracts signed before March 1st, 2025.• The samples must be submitted to BGI’s Hong Kong Lab before March 31st, 2025.• This promotion is exclusively available in Hong Kong and Macau.• This is a limited and conditional offer subject to the actual execution of the contract and BGI Genomics reserves the right to void the promotion.

Exciting Spring Promotions on Sequencing & Mass Spectrometry!

On January 21st, the Thalassemia International Federation (TIF) and BGI Genomics jointly hosted an educational webinar focused on thalassemia prevention in high-prevalence regions. The event featured five international experts from four different countries. Experts emphasized that thalassemia is a preventable disease and high-throughput sequencing (HTS) technologies can accelerate prevention efforts.<img src="https://cdn.it.bgi.com/source/%E5%B0%B1AN%E3%80%81TIF+Webinar+Screenshot.jpg" alt="%E5%B0%B1AN%E3%80%81TIF+Webinar+Screenshot.jpg" data-href="" style=""/>During the webinar, speakers shared insights on key topics, including epidemiological research in Southeast Asia, the application of HTS in genetic testing, and clinical experiences from Thailand, Indonesia, and China in tackling thalassemia prevention. The Global Challenge of Thalassemia<img src="https://cdn.it.bgi.com/source/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171143.png" alt="%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171143.png" data-href="" style=""/>Thalassemia is a preventable disease, but effective prevention and control measures have not been widely implemented. Medical Advisor Dr. Michael Angastiniotis from TIF believes that, “thalassemia prevention is a complex issue. We need to start by educating our public.” In Thailand, with 800,000 newborns, this results in over 4,200 babies potentially facing severe conditions. As Dr. Sakorn Pornprasert from Chiang Mai University shared, “In every 1,000 live births, six could be suffering from severe thalassemia conditions.” The societal burden could amount to approximately $612 million USD over their lifetimes. Dr. Dina Garniasih from Harapan Kita Child and Mother Hospital, under Indonesia’s Ministry of Health, highlighted that while thalassemia rates are rising in Indonesia, the low screening rate exacerbates the issue. Despite medical advancements improving survival rates for patients, the financial burden and pressure on healthcare systems remain substantial challenges. Dr. Michael Angastiniotis, TIF Medical Advisor, also pointed out that many thalassemia-prevalent countries are facing blood donation shortages, creating an additional challenge for patients who rely on regular transfusions. Conventional screening for thalassemia involves hematological analysis, with genetic testing typically performed only for individuals or couples on common variants. However, this approach has limitations, especially for detecting uncommon mutations. In China, Professor Zhu Baosheng from First People’s Hospital of Yunnan Province highlighted concerns about the conventional method. He explained that it requires multiple blood tests and clinic visits, making it time-consuming and potentially missing crucial opportunities for prenatal diagnosis. Additionally, misdiagnoses due to false negatives are still a challenge in high-prevalence regions like southern China. Genetic Testing: Effective for Thalassemia ScreeningTo address these challenges, experts agree that genetic testing should be implemented as the screening method. HTS-based genetic testing offers greater sensitivity and specificity, and it does so without adding significant costs. <img src="https://cdn.it.bgi.com/source/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171152.png" alt="%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171152.png" data-href="" style="width: 100%;"/> The adoption of HTS technology has significantly improved detection rates compared to conventional methods, offering a valuable model for high-prevalence regions. As Prof. Sakorn Pornprasert noted, “NGS is a promising genetic testing method for identifying uncommon gene mutations, which is crucial for thalassemia screening and control.” <img src="https://cdn.it.bgi.com/source/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171155.png" alt="%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171155.png" data-href="" style=""/> In a joint study between Harapan Kita Child and Mother Hospital and BGI Genomics, the integration of HTS into the thalassemia testing improved overall outcomes. Dr. Garniasih pointed out that “Combining NGS and GAP PCR enables single-test detection of alpha and beta mutations, reducing invasiveness and boosting screening rates.” <img src="https://cdn.it.bgi.com/source/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171158.png" alt="%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171158.png" data-href="" style="width: 100%;"/> Active on the front line of preventing birth defects in Yunnan Province, Prof. Zhu, with decades of clinical experience, suggests that thalassemia prevention should focus on identifying carriers and high-risk couples. The HTS-based method is more sensitive and accurate than the traditional method. Advancing Screening with high-throughput Sequencing<img src="https://cdn.it.bgi.com/source/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171149.png" alt="%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250122171149.png" data-href="" style=""/>Advancements in sequencing technology have made HTS, featuring both short-read and long-read sequencing, as a promising technique for thalassemia screening. HTS detected more pathogenic variants and at-risk couples than the traditional method, which incurs no additional cost compared to the conventional strategy. Dr. Peng Zhiyu, Vice President of BGI Genomics, suggested, “High-throughput sequencing-based methods offer a more comprehensive genetic screening for thalassemia.” This new screening strategy of using genetic testing as a first-line screening method reduces the under-detection rate of thalassemia carriers, which are crucial in thalassemia screening. Dr. Peng shared findings from joint studies between BGI Genomics and international health organizations. The studies revealed that HTS detected more thalassemia variants. It also identified variants linked to sickle cell disease and other hemoglobinopathies. Building a Comprehensive Network for Thalassemia PreventionThrough HTS technology, BGI Genomics is working to establish an international academic consortium for thalassemia prevention. This consortium aims to develop and apply new technologies for thalassemia prevention, build a comprehensive database of pathogenic variants, and support the best clinical practices for thalassemia screening and diagnosis. The consortium currently includes members of clinicians, researchers, and patients from China, Thailand, Malaysia, Indonesia, and Vienna. The consortium provides free implementation of new technologies for pilot projects, training programs, and additional support for study design. It also provides HLA typing for thalassemia major families, and this program has successfully performed 20,000 tests for over 7,000 families as of January 2025. We welcome members from all over the world to join the consortium and accelerate the global prevention of thalassemia. For more information, please contact Dr. Peng at pengzhiyu@bgi.com. In summary, the webinar provided valuable insights into the current state of thalassemia prevention and the role of advanced genetic screening technologies. Implementing genetic testing methods such as HTS, regions with high thalassemia prevalence can improve early detection rates, reduce misdiagnoses, and ultimately alleviate the societal and healthcare burdens of this preventable disease. About BGI Genomics<a href="bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.

High-throughput Sequencing Technology Accelerates Global Thalassemia Prevention | TIF Webinar Recap

A colorectal cancer (CRC) screening initiative launched in Harbin, Heilongjiang province, China, in March 2024 has attracted about 830,000 participants for registration, demonstrating significant community engagement. The project, targeting 2.4 million residents aged 45 to 64 over three years, utilizes fecal DNA methylation testing technology from BGI Genomics to identify at-risk individuals efficiently.<img src="https://cdn.it.bgi.com/source/image9165926118.png" alt="image9165926118.png" data-href="" style="">Figure 1. Residents sign up for colorectal cancer screenings in the community.The screening aims to reduce unnecessary colonoscopies and make screening accessible to a broader population. Residents with positive results are eligible for colonoscopies and future pathological examinations at designated hospitals within a year, with costs under US$165 covered by the program. This approach ensures affordable access to necessary procedures and reduces the strain on medical resources, making the model suitable for regions with limited healthcare capacity.Since its launch, the Harbin screening project has gained significant traction. By January 20, about 830,000 residents had registered for the program, and over 750,000 screening reports had been issued. &nbsp;<img src="https://cdn.it.bgi.com/source/image0778642541.png" alt="image0778642541.png" data-href="" style="width: 100%;">Figure 2. A community hospital in Harbin registering residents for colorectal cancer screenings.This large-scale initiative marks a significant step in China’s efforts to combat colorectal cancer, employing a tiered screening approach that has gained attention globally. Many regions in China have adopted a tiered screening strategy to reduce the burden of CRC, inspiring global CRC prevention and control. The tiered screening approach involves using methods like fecal DNA testing or FIT to assess CRC risk, followed by precise screening with colonoscopy for high-risk individuals. This approach reduces unnecessary colonoscopies, making it suitable for regions with constrained medical resources.Early detection of CRC enables less invasive treatment, resulting in lower morbidity, mortality, and treatment costs. Fecal DNA testing, a noninvasive method, has boosted CRC early-screening participation rates, with studies suggesting up to 70% compliance compared to colonoscopy alone.The Harbin initiative is the largest public CRC screening project of its kind in China that utilizes fecal DNA methylation testing for organized efforts. The technology targets genetic mutations and methylation characteristics of colorectal cells, requiring no special equipment, dietary restrictions, or invasive procedures. It has been included in CRC screening guidelines and expert consensus globally. This initiative underscores the importance of early detection and the potential for cost-effective healthcare solutions that could be adapted worldwide.

China's Tiered Screening Model Attracts About 830,000 Participants for Colorectal Cancer Prevention

On January 15, 2025, the Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics in Brunei, launched the National Cervical Cancer Prevention and Control Program along with the 2025 National Guideline. The program aims to enhance early detection and eliminate cervical cancer across Brunei.<img src="https://cdn.it.bgi.com/source/BGI+Genomics+Brunei+HPV+Program+Photo+1+website.jpg" alt="BGI+Genomics+Brunei+HPV+Program+Photo+1+website.jpg" data-href="" style="width: 100%;">Group photo of the launch eventThe launch event was attended by Dato Dr. Hj Mohd Isham, Minister of Health; Maswadi Hj Mohsin, Permanent Secretary of the Ministry of Health, Dr. Du Yutao, Chief Operating Officer of BGI Genomics; Jeremy Cao, Southeast Asia Regional General Manager of BGI Genomics; and other dignitaries. <img src="https://cdn.it.bgi.com/source/BGI+Genomics+Brunei+HPV+Program+Photo+2+website.jpg" alt="BGI+Genomics+Brunei+HPV+Program+Photo+2+website.jpg" data-href="" style="width: 100%;"> Minister Dato Dr. IshamAt the event, Minister Dato Dr. Isham expressed his recognition and gratitude to the medical institutions and companies that participated in the program. He emphasized that the government is actively seeking partnerships with leading global health organizations to enhance the quality and accessibility of healthcare services for all citizens. <img src="https://cdn.it.bgi.com/source/BGI+Genomics+Brunei+HPV+Program+Photo+3+website.jpg" alt="BGI+Genomics+Brunei+HPV+Program+Photo+3+website.jpg" data-href="" style=""/>Minister Dato Dr. Isham (right) and Dr. Du Yutao (left), COO of BGI Genomics &nbsp;“BGI Genomics’ HPV DNA testing can help Brunei efficiently carry out large-scale HPV screening. Looking ahead, we aspire to deepen our collaboration with Brunei to explore innovations in broader public health fields and advance the health and well-being of the Bruneian people,” said Dr. Du.The updated guideline highlights that HPV DNA-based testing as a primary tool for early detection offers a more accurate and reliable method compared to cytology. With royal family authorization and MOH leadership, this national project supports the WHO’s global strategy of cervical cancer elimination by 2030 and demonstrates Brunei’s dedication to local and global health goals.<img src="https://cdn.it.bgi.com/source/BGI+Genomics+Brunei+HPV+Program+Photo+4.png" alt="BGI+Genomics+Brunei+HPV+Program+Photo+4.png" data-href="" style=""/>Minister Dato Dr. Isham (left) and Jeremy Cao (right) jointly present the National Cervical Cancer Prevention and Control Guideline 2025This program incorporates a national HPV DNA screening initiative for all women aged 25 to 65. The HPV self-sampling kits are available at 32 clinics, four hospitals, and three gynecology wards in Brunei's four districts. After the launch, Dato Dr. Isham met with Dr. Du and held in-depth discussions on future colorectal cancer screening program, multi-omics research, expert training and potential projects.As another public health collaboration between BGI Genomics and the Brunei government, this initiative marks the transformation of BGI Genomics’ first Huo-Yan Lab built in an ASEAN country. Through this collaboration, Brunei is taking a step towards a healthier national future. About BGI Genomics<a href="bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.

BGI Genomics Empowers Brunei’s National Cervical Cancer Prevention Program

In the bustling metropolis of Mumbai, a pioneering researcher is making precision medicine both accessible and transformative. With over 14 years of experience in the life sciences industry, Dr. Ajay K. Chaudhary serves as a Senior Field Application Scientist at BGI Genomics, where his expertise in next-generation sequencing (NGS) and technical education helps elevate healthcare solutions.<img src="https://cdn.it.bgi.com/source/LabPhoto1resized.jpg" alt="LabPhoto1resized.jpg" data-href="" style="">Dr. Ajay handles NGS testing samples in the lab, one of his recurring everyday dutiesDr. Ajay’s journey into genomics reflects a deep commitment to turning research insights into practical health solutions. "Science should not just be confined to laboratories; it should touch lives," he says. Starting his academic path at the University of Allahabad, his early research sparked a passion for understanding complex biological systems. This passion led to a PhD in Biotechnology and opportunities at prestigious institutions like Roswell Park Cancer Institute in New York, where he delved and worked on cancer research. Yet, he always felt the pull to bring these insights closer to patients.“When I transitioned to biotechnology, it was like finding the missing piece,” he reflects. “It’s truly rewarding to see how innovation can directly impact healthcare, helping people make informed decisions and improve their lives.”<img src="https://cdn.it.bgi.com/source/BGIHQLabTrainingPhotoresized.jpg" alt="BGIHQLabTrainingPhotoresized.jpg" data-href="" style="">Dr. Ajay during a training with colleagues at BGI Genomics HQ in ShenzhenInnovation in Early DetectionBGI Genomics cutting-edge products, such as Non-Invasive Prenatal Testing (NIPT), <a href="https://www.bgi.com/global/service/bgi-sentis-cancer-discovery-panel" target="_blank">Cancer Panels</a>, and <a href="https://www.bgi.com/global/service/bgi-xome-wes" target="_blank">Whole Exome Sequencing</a>, are making significant strides in the region. NIPT, for example, has offered expectant mothers a safer, non-invasive alternative for genetic screening, reducing the risks associated with traditional methods. Similarly, cancer panels enable earlier and more precise diagnoses, leading to personalized treatment strategies.As part of his role, this dedicated scientist focuses on expanding the reach of genetic testing in India and neighboring regions. He is actively involved in setting up NGS laboratories, conducting technical training, and troubleshooting operational challenges. “The key to successfully implementing genomics lies in education and awareness,” he emphasizes. “By empowering healthcare providers with the right knowledge, we can unlock the full potential of precision medicine.”When looking upon his work achievements, Dr. Ajay highlighted a particularly impactful case: “A young mother who had previously experienced a miscarriage due to invasive testing opted for our <a href="https://www.niftytest.com/" target="_blank">NIFTY&reg; Test</a>. This non-invasive approach provided accurate, reassuring results, allowing her to proceed with her pregnancy without anxiety. Stories like these reinforce the transformative power of genomic technologies.”The Future of HealthcareWhen asked about the future, Dr. Ajay pointed to innovations such as CRISPR gene editing, liquid biopsy technologies, and the integration of artificial intelligence in genomics. “These advancements will redefine healthcare by enabling even more precise diagnostics and treatments,” he said. “In South Asia, where genetic diversity is immense, the potential to improve outcomes is unparalleled.”<img src="https://cdn.it.bgi.com/source/Yogaresized.jpg" alt="Yogaresized.jpg" data-href="" style="">Dr. Ajay on his daily Yoga &amp; Meditation routine. “It brings internal power, wisdom, peace &amp; confidence.“ Outside of his professional life, this hyperactive researcher finds solace in nature. He is an avid gardener and practices yoga to maintain mental clarity and balance. On weekends, when works allows him to, he can often be found horse riding or trekking in the serene landscapes of Himachal Pradesh.<img src="https://cdn.it.bgi.com/source/HorseRidingresized.jpg" alt="HorseRidingresized.jpg" data-href="" style="">Dr. Ajay enjoying a peaceful moment of horse riding in the picturesque Khajjiar town, Himachal Pradesh State, Northern IndiaDr. Ajay’s work exemplifies the crucial role of dedicated professionals in transforming healthcare through genomics. His efforts are advancing science and making tangible differences in the lives of patients across South Asia. As this field continues to evolve, committed experts in the field like him ensure that these innovations reach the communities that need them most.About BGI Genomics<a href="https://www.bgi.com/global/news/bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions and involve more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.

News

BGI Genomics' Joint Venture NGI Signed Research Agreement for Prenatal Genetic Screening in Indonesia

BGI Genomics and TIF Supports High-Throughput Sequencing as Key to Advancing Thalassemia Prevention | The Science Times

Early Screening and Lifestyle Changes Prevent Nearly Half Cancer Cases | World Cancer Day

BGI Genomics' Joint Venture NGI Signed Research Agreement for Prenatal Genetic Screening in Indonesia

BGI Genomics and TIF Supports High-Throughput Sequencing as Key to Advancing Thalassemia Prevention | The Science Times

Early Screening and Lifestyle Changes Prevent Nearly Half Cancer Cases | World Cancer Day

Exciting Spring Promotions on Sequencing & Mass Spectrometry!

High-throughput Sequencing Technology Accelerates Global Thalassemia Prevention | TIF Webinar Recap

China's Tiered Screening Model Attracts About 830,000 Participants for Colorectal Cancer Prevention

BGI Genomics Empowers Brunei’s National Cervical Cancer Prevention Program

From Mumbai to Genomics Impact in South Asia | Dr. Ajay’s Journey